BIO Submits Comments to FDA on Pediatrics Stakeholders Meeting
<p>
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to present our views on pediatric drug development at the March 25 pediatric stakeholder meeting and to submit written comments to the docket. BIO applauds the leadership of the FDA for convening the stakeholder meeting to help foster collaboration and coordination across all pediatrics stakeholders, including industry, academia, the patient advocacy community, and government, so that we can work together to develop safe and effective new therapies for children.</p>
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to present our views on pediatric drug development at the March 25 pediatric stakeholder meeting and to submit written comments to the docket. BIO applauds the leadership of the FDA for convening the stakeholder meeting to help foster collaboration and coordination across all pediatrics stakeholders, including industry, academia, the patient advocacy community, and government, so that we can work together to develop safe and effective new therapies for children.
